Sunvozertinib outperformed platinum-based chemotherapy as first-line treatment in a Phase 3 head-to-head study in advanced NSCLC with EGFR exon 20 insertions. In WU-KONG28 (NCT05668988), median progression-free survival was 10.3 months with sunvozertinib versus 7.5 months with chemotherapy, with an objective response rate of 58.9% versus 31.1%. The study also reported more frequent grade 3+ adverse events with sunvozertinib (75.5% vs. 56.7%), including elevated creatine kinase, diarrhea, and anemia, while investigators reported no deaths attributed to treatment-related adverse events. The results provide another evidence point for early, biomarker-driven use of next-generation EGFR inhibitors. For developers and payors, the trial adds a clearer benchmark for efficacy and tolerability in a genetically defined patient subset where treatment options have historically been limited.